

Prematurely ended - Statement

EudraCT Number: 2007-006126-10

Full title of the study: Pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma

Sponsor-ID: Efalizumab in CTCL

Sponsor: Charité – Universitätsmedizin Berlin

Product: Efalizumab

Study Contact: Prof. Dr. med. Wolfram Sterry
Klinik für Dermatologie, Venerologie und Allergologie

Date of early termination: 11.03.2009

Statement: On behalf of the sponsor, this is confirm that above trial never recruited a patient, due to high health and safety risk for patients. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009. Known side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection.